BioCentury
ARTICLE | Financial News

Oncolytic virus play Oncorus raises $57M

July 19, 2016 7:00 AM UTC

Oncorus Inc. (Cambridge, Mass.) debuted with $57 million in a series A round led by MPM Capital. Deerfield Management, Arkin Bio Ventures, Celgene Corp. (NASDAQ:CELG), Excelyrate Capital, and Long March Investment Fund also participated.

Oncorus is developing oncolytic viral constructs for cancer based on its next-generation oncolytic herpes simplex virus (HSV). Its preclinical lead program is for glioblastoma multiforme (GBM). ...